A pilot study of brexpiprazole for bipolar depression

Edson S Brown, Neusha Khaleghi, Erin A Van Enkevort, Elena Ivleva, Alyson K Nakamura, Traci Holmes, Brittany L Mason, Chastity Escalante

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Past studies suggest that brexpiprazole is an effective adjunctive treatment for major depressive disorder and schizophrenia; however, no studies have examined brexpiprazole for bipolar depression. In this study, we examined the effects of brexpiprazole on mood, cognition, and quality of life in outpatients with bipolar depression. Methods: Twenty-one adults with bipolar disorder (most recent episode depressed) and scoring at least a 25 on the Montgomery-Åsberg Depression Rating Scale (MADRS) were recruited. Brexpiprazole was titrated up to 4 mg/day over the 8-week period. Depressive symptoms were measured using MADRS and Inventory of Depressive Symptomatology Self-report (IDS-SR 30 ). Manic symptoms were measured using Young Mania Rating Scale, quality of life with the Quality of Life in Bipolar Disorder (QOLBD), and cognition with Rey Auditory Verbal Learning Test, Stroop Color Word Test, and Trail Making Test. Results: MADRS and IDS-SR 30 scores decreased from baseline at weeks 4 and 8. YMRS and cognitive scores did not change significantly. QOLBD scores increased from baseline to week 8. Limitations: A limitation to this study is the open-label design. Conclusion: To our knowledge, this is the first study to examine the effects of brexpiprazole on bipolar depression. We found a significant reduction in depressive symptoms and an increase in quality of life.

Original languageEnglish (US)
Pages (from-to)315-318
Number of pages4
JournalJournal of Affective Disorders
Volume249
DOIs
StatePublished - Apr 15 2019

Fingerprint

Bipolar Disorder
Quality of Life
Depression
Cognition
Trail Making Test
Stroop Test
Verbal Learning
Major Depressive Disorder
brexpiprazole
Self Report
Schizophrenia
Outpatients
Color
Equipment and Supplies

Keywords

  • Bipolar disorder
  • Brexpiprazole
  • Cognition
  • Depression

ASJC Scopus subject areas

  • Clinical Psychology
  • Psychiatry and Mental health

Cite this

A pilot study of brexpiprazole for bipolar depression. / Brown, Edson S; Khaleghi, Neusha; Van Enkevort, Erin A; Ivleva, Elena; Nakamura, Alyson K; Holmes, Traci; Mason, Brittany L; Escalante, Chastity.

In: Journal of Affective Disorders, Vol. 249, 15.04.2019, p. 315-318.

Research output: Contribution to journalArticle

@article{0bffb0d4f38e45b38e77dacef20f6ef0,
title = "A pilot study of brexpiprazole for bipolar depression",
abstract = "Background: Past studies suggest that brexpiprazole is an effective adjunctive treatment for major depressive disorder and schizophrenia; however, no studies have examined brexpiprazole for bipolar depression. In this study, we examined the effects of brexpiprazole on mood, cognition, and quality of life in outpatients with bipolar depression. Methods: Twenty-one adults with bipolar disorder (most recent episode depressed) and scoring at least a 25 on the Montgomery-{\AA}sberg Depression Rating Scale (MADRS) were recruited. Brexpiprazole was titrated up to 4 mg/day over the 8-week period. Depressive symptoms were measured using MADRS and Inventory of Depressive Symptomatology Self-report (IDS-SR 30 ). Manic symptoms were measured using Young Mania Rating Scale, quality of life with the Quality of Life in Bipolar Disorder (QOLBD), and cognition with Rey Auditory Verbal Learning Test, Stroop Color Word Test, and Trail Making Test. Results: MADRS and IDS-SR 30 scores decreased from baseline at weeks 4 and 8. YMRS and cognitive scores did not change significantly. QOLBD scores increased from baseline to week 8. Limitations: A limitation to this study is the open-label design. Conclusion: To our knowledge, this is the first study to examine the effects of brexpiprazole on bipolar depression. We found a significant reduction in depressive symptoms and an increase in quality of life.",
keywords = "Bipolar disorder, Brexpiprazole, Cognition, Depression",
author = "Brown, {Edson S} and Neusha Khaleghi and {Van Enkevort}, {Erin A} and Elena Ivleva and Nakamura, {Alyson K} and Traci Holmes and Mason, {Brittany L} and Chastity Escalante",
year = "2019",
month = "4",
day = "15",
doi = "10.1016/j.jad.2019.02.056",
language = "English (US)",
volume = "249",
pages = "315--318",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",

}

TY - JOUR

T1 - A pilot study of brexpiprazole for bipolar depression

AU - Brown, Edson S

AU - Khaleghi, Neusha

AU - Van Enkevort, Erin A

AU - Ivleva, Elena

AU - Nakamura, Alyson K

AU - Holmes, Traci

AU - Mason, Brittany L

AU - Escalante, Chastity

PY - 2019/4/15

Y1 - 2019/4/15

N2 - Background: Past studies suggest that brexpiprazole is an effective adjunctive treatment for major depressive disorder and schizophrenia; however, no studies have examined brexpiprazole for bipolar depression. In this study, we examined the effects of brexpiprazole on mood, cognition, and quality of life in outpatients with bipolar depression. Methods: Twenty-one adults with bipolar disorder (most recent episode depressed) and scoring at least a 25 on the Montgomery-Åsberg Depression Rating Scale (MADRS) were recruited. Brexpiprazole was titrated up to 4 mg/day over the 8-week period. Depressive symptoms were measured using MADRS and Inventory of Depressive Symptomatology Self-report (IDS-SR 30 ). Manic symptoms were measured using Young Mania Rating Scale, quality of life with the Quality of Life in Bipolar Disorder (QOLBD), and cognition with Rey Auditory Verbal Learning Test, Stroop Color Word Test, and Trail Making Test. Results: MADRS and IDS-SR 30 scores decreased from baseline at weeks 4 and 8. YMRS and cognitive scores did not change significantly. QOLBD scores increased from baseline to week 8. Limitations: A limitation to this study is the open-label design. Conclusion: To our knowledge, this is the first study to examine the effects of brexpiprazole on bipolar depression. We found a significant reduction in depressive symptoms and an increase in quality of life.

AB - Background: Past studies suggest that brexpiprazole is an effective adjunctive treatment for major depressive disorder and schizophrenia; however, no studies have examined brexpiprazole for bipolar depression. In this study, we examined the effects of brexpiprazole on mood, cognition, and quality of life in outpatients with bipolar depression. Methods: Twenty-one adults with bipolar disorder (most recent episode depressed) and scoring at least a 25 on the Montgomery-Åsberg Depression Rating Scale (MADRS) were recruited. Brexpiprazole was titrated up to 4 mg/day over the 8-week period. Depressive symptoms were measured using MADRS and Inventory of Depressive Symptomatology Self-report (IDS-SR 30 ). Manic symptoms were measured using Young Mania Rating Scale, quality of life with the Quality of Life in Bipolar Disorder (QOLBD), and cognition with Rey Auditory Verbal Learning Test, Stroop Color Word Test, and Trail Making Test. Results: MADRS and IDS-SR 30 scores decreased from baseline at weeks 4 and 8. YMRS and cognitive scores did not change significantly. QOLBD scores increased from baseline to week 8. Limitations: A limitation to this study is the open-label design. Conclusion: To our knowledge, this is the first study to examine the effects of brexpiprazole on bipolar depression. We found a significant reduction in depressive symptoms and an increase in quality of life.

KW - Bipolar disorder

KW - Brexpiprazole

KW - Cognition

KW - Depression

UR - http://www.scopus.com/inward/record.url?scp=85061819996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061819996&partnerID=8YFLogxK

U2 - 10.1016/j.jad.2019.02.056

DO - 10.1016/j.jad.2019.02.056

M3 - Article

VL - 249

SP - 315

EP - 318

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

ER -